化疗联合亲缘HLA不全相合造血干细胞输注治疗血液系统恶性疾病

 目的　明确化疗联合亲缘HLA不全相合造血干细胞输注治疗血液系统恶性疾病的疗效及安全性。 方法　9例血液系统恶性疾病患者化疗后36 h回输亲缘HLA不全相合造血干细胞，评价其疗效、造血恢复时间及并发症。结果　9例患者包括4例急性髓系白血病、1例急性B淋巴细胞白血病、2例多发性骨髓瘤、1例霍奇金淋巴瘤、1例弥漫大B细胞淋巴瘤；年龄29～67岁；共接受治疗19例（次），每个疗程平均回输单个核细胞计数（3.12±1.29）×108／kg，CD+34 细胞计数（1.71±1.00）×106／kg；CD+3 细胞计数（2.13±0.99）×108／kg。完全缓解4例，部分缓解1例，疾病进展4例。随访2～14个月，生存4例，死亡5例。9例患者输注亲缘HLA不全相合造血干细胞过程顺利，无病例检测到供者嵌合状态，未出现移植物抗宿主病。结论　化疗联合亲缘HLA不全相合造血干细胞输注治疗血液系统恶性疾病操作简单且经济，供者来源丰富且易获得，具有良好的安全性和耐受性。

Chemotherapy combined with infusion related HLA-mismatched hematopoietic stem cells for hematologic malignancies: a novel therapeutic strategy

Objective　To investigate the therapeutic outcomes of chemotherapy with infusion related HLA-mismatched hematopoietic stem cells for hematologic malignancies. Methods　Therapy responses and hematopoietic recovery as well as complications of 9 patients were analyzed. Results　In the 9 patients aged 29－67 years, four were acute myeloid leukemia, one was acute B lymphocytic leukemia, two were multiple myeloma, one was Hodgkin's disease, one was diffuse large B cell lymphoma.　The average of MNC was (3.12±1.29)×108/kg, CD＋34 cells was (1.71±1.00)×106/kg, and CD＋3 cells was (2.13±0.99)×108/kg. There was complete remission in four patients, partial remission in one, disease progression in four. Following up 2 to 14 months, four patients were in survival. No donor chimerism was detected and no graft-versus-host disease was observed in any patient. Conclusion　Chemotherapy with infusion related HLA-mismatched hematopoietic stem cells for hematologic malignancies may provide a promising treatment method as a novel therapeutic strategy.